Shopping Cart
- Remove All
- Your shopping cart is currently empty
VU534 is a NAPE-PLD agonist with an EC50 of 0.30 μM.VU534 is a dual inhibitor of FAAH and sEH, with an IC50 of 1.2 μM for sEH.VU534 is used in diseases related to cardiometabolism.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $36 | In Stock | |
5 mg | $84 | In Stock | |
10 mg | $139 | In Stock | |
25 mg | $235 | In Stock | |
50 mg | $353 | In Stock | |
100 mg | $533 | In Stock |
Description | VU534 is a NAPE-PLD agonist with an EC50 of 0.30 μM.VU534 is a dual inhibitor of FAAH and sEH, with an IC50 of 1.2 μM for sEH.VU534 is used in diseases related to cardiometabolism. |
Targets&IC50 | NAPE-PLD:0.30 μM(EC50), FAAH:1.2 μM, sEH:1.2 μM |
In vitro | VU534 (30 μM; 24 h) is less cytotoxic to HepG2 and Raw264.7 cell lines.[1] VU534 (3~30 μM; 1 h) can increase NAPE-PLD activity in Raw264.7 cells.[1] VU534 (1 h) can increase NAPE-PLD activity in HepG2 cells with an EC50 value of 1.5 μM.[1] VU534 (5 μM, 1 h) increased NAPE-PLD activity 1.5-fold but did not reverse NAPE-PLD activity inhibited by LEI–401.[1] VU534 (10 μM; 6 h) significantly enhances efferocytosis of bone marrow-derived macrophages but cannot exert this effect when Napepld is knocked out.[1] |
Molecular Weight | 447.55 |
Formula | C21H22FN3O3S2 |
Cas No. | 923509-20-0 |
Storage | Shipping with blue ice. |
Solubility Information | DMSO: <1 mg/mL (insoluble or slightly soluble), Sonication is recommended. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.